APREs Earnings Beat Hides 98% Revenue Drop and Prolonged Decline

Aprea Therapeutics (APRE) reported fiscal 2025 Q4 earnings on March 16, 2026, with a GAAP EPS of -$0.32, which beat expectations by $0.07. The company narrowed its net loss by 15.2% to $-2.46 million, while revenue plummeted 98.4% to $3.34K. CEO Oren Gilad highlighted strengthened financial flexibility through recent private placements and outlined guidance to fund operations through Q1 2027.

Revenue

The total revenue of Aprea Therapeutics decreased by 98.4% to $3337 in 2025 Q4, down from $205817 in 2024 Q4.

Earnings/Net Income

Aprea Therapeutics narrowed losses to $0.30 per share in 2025 Q4 from a loss of $0.53 per share in 2024 Q4 (43.2% improvement). Meanwhile, the company successfully narrowed its net loss to $-2.46 million in 2025 Q4, reducing losses by 15.2% compared to the $-2.89 million net loss reported in 2024 Q4. This modest improvement in per-share losses reflects progress in cost management despite ongoing operational challenges.

Post-Earnings Price Action Review

The strategy of buying Aprea Therapeutics (APRE) shares after its revenue drop quarter-over-quarter on the financial report released date and holding for 30 days shows poor performance over the past three years. The APRE stock declined in value by 54.70% over the last 52 weeks, with a significant decrease in the first 50 days following the earnings release. The relative strength index (RSI) remained at 42.19, indicating a lack of buying momentum. The enterprise value was negative, and the company's financials showed a significant loss per share of $1.93. The stock price dropped sharply in the initial 50 days following the earnings release, with this decline persisting over the longer 52-week period, reflecting a persistent bearish trend. The stock's RSI remained below 50, suggesting weak buying pressure and ongoing negative sentiment. The negative enterprise value and substantial loss per share underscored the company's financial struggles, contributing to poor post-earnings performance.

CEO Commentary

Oren Gilad, Ph.D., President and CEO of Aprea, highlighted 2025 as a year of “meaningful execution,” emphasizing early clinical proof of concept for APR-1051 with two partial responses in PPP2R1A-mutated endometrial cancer patients. He noted strengthened financial flexibility via late 2025 and early 2026 private placements, which raised $3.1 million and $5.6 million, respectively. Gilad expressed optimism about APR-1051’s potential as a differentiated WEE1 inhibitor and reinforced the company’s focus on advancing DDR portfolio programs to improve patient outcomes and shareholder value. Strategic priorities include optimizing APR-1051’s therapeutic window, exploring combination therapies for ATRN-119, and leveraging a robust balance sheet to execute key milestones.

Guidance

Aprea expects to report additional ACESOT-1051 trial data in Q2 2026, including updates on dose escalation and patient enrollment at key levels (220 mg). The company anticipates sufficient cash and cash equivalents ($14.6 million as of Dec. 31, 2025, plus January 2026 private placement proceeds) to fund operations through Q1 2027. Forward-looking plans include evaluating ATRN-119 in combination therapies (e.g., radiation, immuno-oncology) and advancing investigator-led studies. The CEO reiterated confidence in the DDR portfolio’s potential to deliver “differentiated targeted therapies” but acknowledged inherent risks in clinical development, including uncertainty in trial outcomes and regulatory pathways.

Additional News

Aprea Therapeutics recently secured $5.6 million through a January 2026 private placement, augmenting its $14.6 million in cash reserves as of December 31, 2025. The CEO emphasized strategic priorities, including optimizing APR-1051’s therapeutic window and exploring ATRN-119 combination therapies, to advance its DNA damage response (DDR) portfolio. Additionally, the company announced plans to evaluate ATRN-119 alongside radiation and immuno-oncology treatments, signaling a shift toward multi-modal therapeutic approaches.